Eruptive Melanocytic Nevi in the Setting of Encorafenib, Cetuximab, and Binimetinib Combination Therapy: A Case Report

By sjmartinez • June 4, 2024

Lam K, Gates GA, Bach DQ, Cheng K. Eruptive Melanocytic Nevi in the Setting of Encorafenib, Cetuximab, and Binimetinib Combination Therapy: A Case Report. Case Rep Dermatol. 2024 May 28;16(1):133-139. doi: 10.1159/000539058. PMID: 38831934; PMCID: PMC11147515.

Tags: binimetinib, BRAF inhibitor, BRAF V600E, Case report, Cetuximab, Dermatology, EGFR inhibitor, Encorafenib, Eruptive melanocytic nevi, MEK inhibitor, Publications

Whole genome sequence of the syntrophic benzoate-degrading bacterium, Syntrophus buswellii DSM 102354T

Gunsalus RP, Humm E, Cook L, Wofford NQ, James KL, Pellegrini M, Morselli M, Ha SM, McInerney MJ. Whole genome sequence of the syntrophic benzoate-degrading[...]

Squamous Eccrine Ductal Carcinoma: A Comprehensive Review of the Clinicopathologic Features and Management in 27 Cases

Gudino-Rosales S, Lilley CM, Gates G, Kneiber D. Squamous Eccrine Ductal Carcinoma: A Comprehensive Review of the Clinicopathologic Features and Management in 27 Cases. Cureus.[...]

Brodalumab: Seven-Year US Pharmacovigilance Report

Lebwohl MG, Koo JY, Armstrong AW, Strober BE, Yoon SH, Rawnsley NN, Goehring EL Jr, Jacobson AA. Brodalumab: Seven-Year US Pharmacovigilance Report. Dermatol Ther (Heidelb).[...]